
ADRx, Inc.: A California-based biopharmaceutical firm innovating novel drugs for amyloid diseases.
ADRx, Inc., founded in Westlake Village, California, is a pre-clinical stage biopharmaceutical company focused on developing novel drugs to treat amyloid diseases. Leveraging breakthrough technology, ADRx transforms atomic structures into small molecule therapies targeting conditions such as Alzheimer’s, ALS, and Parkinson’s Disease. The company is pioneering the application of structure-based design to disrupt protein aggregation diseases, aiming to address significant unmet medical needs in neurodegenerative disorders.
Notable figures associated with ADRx include leading scientists and industry experts in biopharmaceuticals. The company has garnered attention for its innovative drug discovery platform and its ability to identify, design, and develop therapeutics based on patient-derived pathological proteins. ADRx’s advancements have the potential to significantly impact the treatment landscape for amyloid diseases, positioning it as a key player in the field of neurodegenerative disease research.

Amydis
amydis.com

Adarx Pharmaceuticals
adarx.com

Amygdala Neurosciences
amygns.com

Pharmatrophix
pharmatrophix.com

Attralus
attralus.com

Amylyx Pharmaceuticals
amylyx.com

Adcentrx Therapeutics
adcentrx.com

NeuroX1
neurox1.com

Neomorph
neomorph.com

NeuroGenetic Pharmaceuticals

AltPep
altpep.com

LadRx
ladrxcorp.com

Oligomerix
oligomerix.com

Agentix
agentixcorp.com

Adenios
Companies similar to Adrx include Amydis, Adarx Pharmaceuticals, Amygdala Neurosciences and Pharmatrophix.
Adrx was founded in 2013.
Adrx's headquarters is located in Thousand Oaks, CA, US.
Adrx's most recent funding round was for $12.1M (USD) in October 2020.
As of Oct 13, 2020, Adrx has raised a total of $24.3M (USD).
Adrx has 9 employees as of Feb 5, 2024.